Dombrovski, Alexandre Y., Mulsant, Benoit H., Ferrell, Robert E., Lotrich, Francis E., Rosen, Jules I., Wallace, Meredith, Houck, Patricia R., Mazumdar, Sati, Pollock, Bruce G.

The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]

Green, Robert C., Roberts, J. Scott, Cupples, L. Adrienne, Relkin, Norman R., Whitehouse, Peter J., Brown, Tamsen, Eckert, Susan LaRusse, Butson, Melissa, Sadovnick, A. Dessa, Quaid, Kimberly A., Chen, Clara, Cook-Deegan, Robert, Farrer, Lindsay A.

Background: The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer’s disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure in a prospective, randomized, controlled trial.; Methods: We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer’s disease to receive […]

Angelucci, Francesco, Bernardini, Sergio, Gravina, Paolo, Bellincampi, Lorenza, Trequattrini, Alberto, Di Iulio, Fulvia, Vanni, Diego, Federici, Giorgio, Caltagirone, Carlo, Bossù, Paola, Spalletta, Gianfranco

Although the etiology of psychotic symptoms (hallucinations and delusions) in Alzheimer’s disease is still not known, alterations in serotonergic neurotransmission have been proposed. In a 3-year follow-up study, we evaluated the association of serotonin (5-HT) receptor 5-HT2a 102T/C polymorphism (allelic variants CC, CT and TT) with psychotic symptom severity and response to treatment with atypical […]

Albani, Diego, Martinelli Boneschi, Filippo, Biella, Gloria, Giacalone, Giacomo, Lupoli, Sara, Clerici, Francesca, Benussi, Luisa, Ghidoni, Roberta, Galimberti, Daniela, Squitti, Rosanna, Mariani, Stefania, Confaloni, Annamaria, Bruno, Giuseppe, Mariani, Claudio, Scarpini, Elio, Binetti, Giuliano, Magnani, Giuseppe, Franceschi, Massimo, Forloni, Gianluigi

Alzheimer’s disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients’ genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with […]